Updated on 7 June 2016
The Global Health Innovative Technology Fund (GHIT Fund) has announced ten new funding partnerships that include major global pharmaceutical and biotechnology companies and collaborations that will expand investments into research and development (R&D) for neglected diseases worldwide, many of which have already begun to show progress in clinical trials.
The new collaborations include a full funding partnership with Fujifilm Corporation, an associate partnership with Otsuka Pharmaceutical, affiliate partnerships with GlaxoSmithKline, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe Pharma Corporation, Nipro Corporation, Sumitomo Dainippon Pharma, and a sponsorship from Salesforce.com.
The GHIT Fund is a public-private partnership between the Japanese government, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, the Wellcome Trust, and UNDP. Launched in April 2013 with an initial commitment of more than $100 million and now with capital of approximately $140 million, the organization taps Japanese research and development (R&D) to fight neglected diseases.
GHIT invests and manages a portfolio of development partnerships aimed at neglected diseases that afflict the world's poorest people. GHIT mobilizes Japanese pharmaceutical companies and academic and research organizations to engage in the effort to get new medicines, vaccines, and diagnostic tools to people who need them most, with Japan quickly becoming a game-changer in global health.
"We are excited to welcome these new funding partners from within Japan and across the globe, who have joined forces with the GHIT Fund because of their own unique commitments to global health, as well as their confidence that working together will transform R&D," GHIT Fund CEO Dr B T Slingsby said. "The partnerships will not only broaden our scope, but also increase our ability to reach the world's most vulnerable people with lifesaving technology."